Progressive Investment Management Corp Has $8.81 Million Stock Position in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Progressive Investment Management Corp lessened its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 3.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 21,312 shares of the company’s stock after selling 686 shares during the period. IDEXX Laboratories accounts for 2.3% of Progressive Investment Management Corp’s holdings, making the stock its 20th biggest holding. Progressive Investment Management Corp’s holdings in IDEXX Laboratories were worth $8,811,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of IDXX. Cerity Partners LLC increased its position in IDEXX Laboratories by 25.2% during the 3rd quarter. Cerity Partners LLC now owns 10,924 shares of the company’s stock valued at $5,519,000 after purchasing an additional 2,202 shares during the period. Kingsview Wealth Management LLC acquired a new stake in shares of IDEXX Laboratories during the third quarter worth $507,000. Centaurus Financial Inc. acquired a new stake in shares of IDEXX Laboratories during the third quarter worth $115,000. FMR LLC raised its stake in IDEXX Laboratories by 3.6% during the third quarter. FMR LLC now owns 290,861 shares of the company’s stock worth $146,949,000 after buying an additional 10,017 shares during the last quarter. Finally, D.A. Davidson & CO. lifted its holdings in IDEXX Laboratories by 9.5% in the third quarter. D.A. Davidson & CO. now owns 1,629 shares of the company’s stock valued at $823,000 after buying an additional 142 shares during the period. Institutional investors own 87.84% of the company’s stock.

Insider Activity at IDEXX Laboratories

In other IDEXX Laboratories news, EVP George Fennell sold 9,986 shares of the firm’s stock in a transaction on Monday, February 10th. The stock was sold at an average price of $462.53, for a total transaction of $4,618,824.58. Following the transaction, the executive vice president now directly owns 8,176 shares in the company, valued at approximately $3,781,645.28. This trade represents a 54.98 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director M Anne Szostak sold 3,000 shares of the company’s stock in a transaction on Friday, February 7th. The stock was sold at an average price of $465.94, for a total transaction of $1,397,820.00. Following the completion of the sale, the director now owns 3,061 shares of the company’s stock, valued at approximately $1,426,242.34. The trade was a 49.50 % decrease in their position. The disclosure for this sale can be found here. 2.11% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on the company. Barclays lifted their price objective on IDEXX Laboratories from $481.00 to $520.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 4th. Piper Sandler lifted their target price on IDEXX Laboratories from $435.00 to $510.00 and gave the stock a “neutral” rating in a report on Monday, February 10th. Bank of America increased their price target on IDEXX Laboratories from $475.00 to $535.00 and gave the stock a “neutral” rating in a report on Tuesday, February 4th. Leerink Partnrs upgraded shares of IDEXX Laboratories to a “strong-buy” rating in a research report on Monday, December 2nd. Finally, Morgan Stanley reduced their price target on shares of IDEXX Laboratories from $559.00 to $550.00 and set an “overweight” rating for the company in a report on Wednesday, January 29th. Four investment analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, IDEXX Laboratories has a consensus rating of “Moderate Buy” and a consensus price target of $533.75.

IDEXX Laboratories Stock Down 1.6 %

Shares of NASDAQ IDXX opened at $415.87 on Friday. The company has a debt-to-equity ratio of 0.28, a current ratio of 1.31 and a quick ratio of 0.95. The company has a 50-day moving average price of $437.07 and a 200-day moving average price of $443.27. The stock has a market capitalization of $33.71 billion, a P/E ratio of 38.98, a P/E/G ratio of 3.41 and a beta of 1.39. IDEXX Laboratories, Inc. has a 1 year low of $398.50 and a 1 year high of $548.88.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.